Monitor for any future amendments that increase the stake above 5.4% or a conversion to Schedule 13D if the fund's intent changes. The passive nature and moderate size suggest limited near-term trading impact.
AGEN drugs
AGEN drug pipeline →Price Chart
How similar events traded
Executive Summary
Eventide Asset Management disclosed a 5.4% passive stake in Agenus Inc via Schedule 13G, representing 2,446,789 shares held through its Healthcare & Life Sciences Fund as of September 30, 2026. The filing certifies no intent to influence control, and the stake size is modest relative to the company's $327M market cap.
Key Financial Metrics
Key Facts
- Eventide Asset Management filed Schedule 13G disclosing beneficial ownership of 2,446,789 shares of Agenus common stock
- Stake represents 5.4% of outstanding shares as of September 30, 2026
- Shares are held via Eventide Healthcare & Life Sciences Fund, a registered investment company
- Filing certifies passive intent under Rule 13d-1(b) with no purpose of changing or influencing control
- Joint filers include Finny Kuruvilla and Robin C. John, each disclaiming beneficial ownership
Financial Impact
2,446,789 shares, 5.4% of outstanding, valued at approximately $17.7M based on $327M market cap
Risk Factors
- Passive 13G status could change if Eventide later engages with management or seeks board representation
- Fund could reduce position without further public disclosure until below 5%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001580642-26-007713 |
| Document: 0001580642-26-007713-index.html | 0001580642-26-007713 |
| Document: 0001580642-26-007713.txt | 0001580642-26-007713 |
Track record
12 reports on AGEN
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.35 Now $6.29 −0.94% settles Feb 16
- Nov 13, 20263d ago SC 13G Neutral 3/10 Viewing Entry $6.97 Now $6.29 −9.76% settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers